Fasudil
- Generic Name
- Fasudil
- Drug Type
- Small Molecule
- Chemical Formula
- C14H17N3O2S
- CAS Number
- 103745-39-7
- Unique Ingredient Identifier
- Q0CH43PGXS
- Background
Fasudil has been investigated in Carotid Stenosis.
- Indication
用于改善蛛网膜下隙出血后的脑血管痉挛及伴发的脑缺血症状。
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT01935518
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis
Phase 2
Terminated
- Conditions
- Carotid Stenosis
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT00670202
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 17
- Registration Number
- NCT00498615
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
The Effect of Fasudil on Vascular Function in Humans
Phase 2
Completed
- Conditions
- AtherosclerosisHypercholesterolemia
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2008-09-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00120718
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath